In a randomized controlled study, adding metformin to androgen deprivation therapy for low-tumor-volume metastatic hormone-sensitive prostate cancer significantly delayed development of castration-resistant disease.
Investigators sought to assess the impact of treatment with SGLT2 inhibitors on risk of all-cause mortality, cardiovascular disease, or hospitalization for heart failure or chronic kidney disease in patients with type 2 diabetes.
Lower exacerbation counts, fewer health care encounters for asthma symptoms seen in asthma patients with T2D initiating GLP-1R agonists
In a case series, SARS-CoV-2 antibody titers increased after the third dose in a third of patients who previously had no response to vaccination.
Weight loss partly accounted for the association between high parathyroid hormone levels and mortality among patients on hemodialysis.
The proportion of patients with lupus nephritis achieving renal response with belimumab increased during a 6-month extension study.
More than two-thirds of patients experienced a more than 5% weight loss with 12 months of etelcalcetide treatment.
Etelcalcetide use in patients with diabetic nephropathy might protect against development of adynamic bone disease, according to investigators.
Most men with metastatic castration-sensitive prostate cancer (mCSPC) in 2018 did not receive advanced therapies in addition to androgen deprivation therapy (ADT) as first-line treatment for their disease as recommended by clinical practice guidelines, according to real-world data presented at the American Society of Clinical Oncology 2021 virtual annual meeting. This lack of therapeutic intensification…
Nivolumab treatment for patients who have undergone radical surgery for high-risk muscle-invasive urothelial carcinoma improves their disease-free survival compared with placebo, a study shows.
